Researchers at the University of Alberta are utilizing their new insights into the mechanism of action of FOXM-1 inhibitors to design first in class oncology drugs targeting FOXM-1 protein. In addition, novel radiolabeled probes can detect FOXM-1 expressing tumor tissue for companion diagnostic purposes.
FOXM-1 is a transcription factor involved in cancer cell proliferation. Its expression is upregulated in a number of human malignancies including lung cancer, glioblastoma, prostate cancer, basal cell carcinoma and breast cancer. Several studies report that direct or indirect inhibition of this protein’s transcriptional activity by small molecule drugs and RNAi knockdown, correlates well with a potentially significant anticancer profile. Clinical investigations indicate that FOXM1 could be a stable prognostic marker in surgical resection and chemotherapy patients, including renal cancer, pancreatic cancer, liver cancer, cervical cancer and breast cancer, making FOXM-1 a promising companion diagnostic / drug target.
- Novel mechanism of action provides an opportunity for designing new inhibitors
- Application in cancer diagnosis and as a companion diagnostic
We are seeking pharmaceutical and diagnostic companies for collaborative development and licensing.
Technology Management Group
TEC Edmonton – University of Alberta